Literature DB >> 21450904

Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.

Rakhee Vaidya1, Domenica Caramazza, Kebede H Begna, Naseema Gangat, Daniel L Van Dyke, Curtis A Hanson, Animesh Pardanani, Ayalew Tefferi.   

Abstract

Survival in cytogenetically high-risk patients with acute myeloid leukemia or myelodysplastic syndromes is significantly worse in the presence of a monosomal karyotype (MK). The objective of the present study was to determine whether the same held true for primary myelofibrosis. Among 793 primary myelofibrosis patients seen at our institution, 62 displayed an unfavorable karyotype by way of complex karyotype (n = 41) or sole trisomy 8 (n = 21). Seventeen (41%) of the 41 patients with complex karyotype were classified as having an MK. Median survival was 6, 24, and 20 months in patients with MK, complex karyotype without monosomies, and sole trisomy 8, respectively (P < .0001). The corresponding 2-year leukemic transformation rates were 29.4%, 8.3%, and 0 (P < .0001); hazard ratios (95% confidence intervals) were 6.9 (1.3-37.3) and 14.8 (1.7-130.8). The prognostic relevance of MK was not accounted for by the Dynamic International Prognostic Scoring System. We conclude that MK in primary myelofibrosis is associated with extremely poor overall and leukemia-free survival.

Entities:  

Mesh:

Year:  2011        PMID: 21450904     DOI: 10.1182/blood-2010-11-320002

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Authors:  A Tefferi; T L Lasho; C M Finke; R A Knudson; R Ketterling; C H Hanson; M Maffioli; D Caramazza; F Passamonti; A Pardanani
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

Review 3.  Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Authors:  Yahya Daneshbod; Leila Kohan; Vahideh Taghadosi; Olga K Weinberg; Daniel A Arber
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

4.  One thousand patients with primary myelofibrosis: the mayo clinic experience.

Authors:  Ayalew Tefferi; Terra L Lasho; Thitina Jimma; Christy M Finke; Naseema Gangat; Rakhee Vaidya; Kebede H Begna; Aref Al-Kali; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 5.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Authors:  Vikas Gupta; Parameswaran Hari; Ronald Hoffman
Journal:  Blood       Date:  2012-06-14       Impact factor: 22.113

Review 6.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 7.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

8.  Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera.

Authors:  Gene Shaw; Richard Berg
Journal:  Clin Med Res       Date:  2019-10-03

Review 9.  Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.

Authors:  Nisha R Singh
Journal:  Transl Pediatr       Date:  2015-04

Review 10.  Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Authors:  Francesco Passamonti; Barbara Mora; Daniela Barraco; Margherita Maffioli
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.